TNGX

Shares of Tango Therapeutics TNGX surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat. The study is assessing vopimetostat plus one of Revolution Medicines’ RVMD experimental RAS inhibitors — daraxonrasib or zoldonrasib — in previously treated patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The strongest results were reported from the vopimetostat-daraxonrasib arm. Among 12 evaluable patients, the combination achieved an objective response rate (ORR) of 92%, with a disease control rate (DCR) of 100% and a six-month progression-free survival (PFS) rate of 90%. In contrast, the vopimetostat-zoldonrasib combination achieved a 52% ORR across 27 evaluable patients, a DCR of 96% and a six-month PFS rate of 74%. Both combinations were generally well tolerated. The data drew significant attention from investors and analysts, many of whom were particularly impressed by the vopimetostat-daraxonrasib results. Investors also welcomed the company's decision to advance this combination into late-stage development for first-line MTAP-deleted pancreatic cancer. Management believes the findings support the broader strategy of combining PRMT5 inhibition with RAS-targeted therapies and reinforce the potential for a chemotherapy-free treatment option in patients with MTAP-deleted pancreatic cancer. Year to date, the company’s shares have skyrocketed 249% against the industry’s 3% fall. Image Source: Zacks Investment Research The drug is a selective PRMT5 inhibitor designed to target cancers harboring MTAP deletions, a genetic alteration found across multiple tumor types, including pancreatic cancer. Apart from the above study, vopimetostat is also being tested as a monotherapy in a phase I/II study across MTAP-deleted solid tumors. Data from this study is expected later this year. In March, Tango Therapeutics entered into a clinical trial collaboration and supply agreement with Erasca ERAS. Under the agreement, the companies will evaluate vopimetostat in combination with ERAS' pan-RAS molecular glue, ERAS-0015, in patients with MTAP-deleted RAS-mutant cancers. Tango plans to initiate a phase I/II study before year-end, further expanding the development opportunities for vopimetostat. Tango Therapeu...

Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial. TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medicines, and the pancreatic cancer trial appears to have validated its therapeutic approach in a particularly difficult-to-treat cancer type. Billionaire Jeff Bezos Says America Needs to ‘Fix It at the Root’ Like Amazon Does Instead of Picking Villains — Bottom 50% Should Pay ‘Zero’ Taxes Ahead of Oracle Earnings, Here's What Barchart Data Says Comes Next for ORCL Stock Dear Nvidia Stock Fans, Mark Your Calendars for June 11 Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Pancreatic cancer remains one of the most lethal malignancies worldwide, with limited treatment options — making any positive clinical signal extremely valuable. Including recent gains, Tango Therapeutics shares are up more than 200% versus the start of 2026. Tango’s management moved swiftly to capitalize on the post-results momentum by announcing a major capital raise. The biotech firm launched an underwritten public offering worth $500 million on June 8, with an additional 30-day option for underwriters to purchase up to $75 million in additional shares. The timing of this offering is highly strategic, as TNGX is leveraging enthusiasm following its pancreatic cancer clinical trial data to raise capital at what it presumably views as favorable terms. Note that TNGX shares are now trading at an all-time high. The $500 million offering looks substantial for a clinical-stage biotech and signals management’s confidence in advancing its pipeline aggressively. All shares in the offering are being sold directly by the company, meaning the proceeds will fund continued clinical development and potential expansion into additional indications. This capital raise places Tango within a broader wave of biotech dealmaking and financing activity visible in the current market environment, where oncology assets continue to command premium valuations. Companies like Roche (RHHBY), Johnson & Johnson (JNJ), and Incyte (INCY) have recently made multi-billion-dollar acquisitions of cancer-focused biotechs, underscoring exceptional demand for i...

Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat,

Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines' results in pancreatic cancer.

Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 11 Best Day Trading Stocks to Buy Now. Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock. Mizuho’s coverage came after the precision oncology company reported its earnings for the fourth quarter and full year 2025. The results saw Tango Therapeutics Inc. (NASDAQ:TNGX) post $343 million in cash and outline that it expected to have runway beyond 2028. The firm also outlined that it was on track to start a study for pancreatic cancer treatment and added that it had entered into an agreement for evaluating a molecular glue in a clinical trial. Wedbush also discussed Tango Therapeutics Inc. (NASDAQ:TNGX)’s shares in March. It raised the share price target to $19 from $15 and kept an Outperform rating on the stock. The financial firm outlined that it expected Tango Therapeutics Inc. (NASDAQ:TNGX)’s vopimetostat treatment for pancreatic cancer to enter its first major study in 2026. Tango Therapeutics Inc. (NASDAQ:TNGX) is a biotechnology company focusing on cancer treatments. It is headquartered in Boston, Massachusetts. While we acknowledge the potential of TNGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Follow Insider Monkey on Google News.

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. “We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portfolio in 2025,” said Malte Peters, M.D., President and CEO of Tango Therapeutics. “Our lead clinical program, vopimetostat, continues to demonstrate best-in-class potential, and we are on track to launch our first pivotal study in 2L pancreatic cancer this year. Strong enrollment continues in the combination study with Revolution Medicines’ RAS(ON) inhibitors, and we are encouraged by the early safety and efficacy data. Given the differentiated profile of vopimetostat enabling the potential for efficacious and tolerable RAS inhibitor combinations, we have entered into a supply agreement with Erasca for its pan-RAS molecular glue ERAS-0015 to further explore the potential of vopimetostat as the preferred PRMT5 inhibitor for combination therapy in pancreatic cancer and other tumor types. These activities are supported by our robust balance sheet, which provides cash runway into 2028, and plans to allocate capital with discipline in areas where we are best positioned to create significant value for patients.” Clinical Pipeline Updates Vopimetostat – MTAP Selective Once-Daily PRMT5 Inhibitor Pivotal Study in Pancreatic Cancer. The company is on track to initiate a pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer, with initiation anticipated in 2026. Phase 1/2 RAS(ON) Inhibitors Combination Study. Robust enrollment in the vopimetostat + RAS(ON) inhibitors combinat...

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 – BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. “We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult-to-treat MTAP-del cancers, beginning with pancreatic cancer,” said Barbara Weber, M.D., President and CEO of Tango Therapeutics. “The data we presented support our planned pivotal trial in 2L MTAP-del pancreatic cancer with an anticipated study start in 2026. Our ongoing study of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors is also progressing well and we look forward to sharing an update from that study in 2026. Our clinical development plans are supported by our strong balance sheet, reinforced by our recent $225 million financing, which extends our cash runway into 2028. Additionally, we expect a strong cadence of value creating milestones in 2026.” Pipeline Update Vopimetostat (TNG462) Clinical Update In October 2025, vopimetostat clinical data were announced in a corporate presentation. With a mPFS of 7.2 months, the data support the planned pivotal study in 2L MTAP-del pancreatic cancer anticipated to start in 2026. There is robust enrollment in the ongoing combination study of vopimetostat + RAS(ON) inhibitors in 2L+ MTAP-del, RAS-mut pancreatic and lung cancer patients. Vopimetostat in combination with either daraxonrasib or zoldonrasib have been well-tolerated to date with exposures in the active range for each compound. Initial data from the Phase 1/2 study are anticipated in 2026. The lung cancer cohort of the phase 1/2 single agent v...

Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1,200.00%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.35, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Tango Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $53.81 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 23.20%. This compares to year-ago revenues of $11.61 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tango Therapeutics shares have added about 159.2% since the beginning of the year versus the S&P 500's gain of 16.5%. While Tango Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Tango Therapeutics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list...

This article first appeared on GuruFocus. Tango Therapeutics Inc (NASDAQ:TNGX) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $37.14 million, and the earnings are expected to come in at -$0.05 per share. The full year 2025's revenue is expected to be $49.66 million and the earnings are expected to be -$1.09 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 5 Warning Signs with TNGX. Is TNGX fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Tango Therapeutics Inc (NASDAQ:TNGX) have increased from $28.43 million to $49.66 million for the full year 2025. However, for 2026, they have declined from $25.77 million to $13.97 million over the past 90 days. Earnings estimates for the full year 2025 have improved from -$1.39 per share to -$1.09 per share. For 2026, earnings estimates have slightly increased from -$1.35 per share to -$1.34 per share over the past 90 days. In the previous quarter ending 2025-06-30, Tango Therapeutics Inc's (NASDAQ:TNGX) actual revenue was $3.18 million, which missed analysts' revenue expectations of $6.68 million by -52.37%. Tango Therapeutics Inc's (NASDAQ:TNGX) actual earnings were -$0.35 per share, which beat analysts' earnings expectations of -$0.36 per share by 3.85%. After releasing the results, Tango Therapeutics Inc (NASDAQ:TNGX) was up by 4.86% in one day. Based on the one-year price targets offered by 8 analysts, the average target price for Tango Therapeutics Inc (NASDAQ:TNGX) is $12.13 with a high estimate of $15.00 and a low estimate of $8.00. The average target implies an upside of 49.51% from the current price of $8.11. Based on GuruFocus estimates, the estimated GF Value for Tango Therapeutics Inc (NASDAQ:TNGX) in one year is $2.78, suggesting a downside of -65.72% from the current price of $8.11. Based on the consensus recommendation from 9 brokerage firms, Tango Therapeutics Inc's (NASDAQ:TNGX) average brokerage recommendation is currently 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

On October 23, 2025, Tango Therapeutics announced positive data from its Phase 1/2 trial of Vopimetostat (TNG462) in MTAP-deleted cancers and completed both a US$209.99 million follow-on equity offering and a US$15 million private placement led by Nextech Invest Ltd. This combination of encouraging clinical trial results and successful capital raises marks a pivotal step for Tango's research progress and future funding capability. We'll explore how the clinical progress with Vopimetostat shapes Tango Therapeutics' investment narrative and overall outlook. The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To be a Tango Therapeutics shareholder, you need to believe in the company’s ability to transform its strong scientific pipeline into commercial success, despite ongoing unprofitability, large cash burn, and aggressive valuation multiples. The recent announcement of positive Phase 1/2 data on Vopimetostat and the completion of a sizeable US$210 million equity offering, plus an additional US$15 million private placement, may shift the short-term narrative. Previously, the biggest catalysts hinged on clinical progress and sufficient funding, while risks focused on dilution and rising losses. With more capital on hand and promising clinical data, immediate funding risk is reduced, and attention now pivots toward upcoming trial milestones and the coming end of lock-up agreements in December. The latest news strengthens Tango’s ability to advance its research, but persistent losses and dilution risk remain significant factors to watch. Yet, the potential impact of those lock-up expiries could catch some by surprise. Upon reviewing our latest valuation report, Tango Therapeutics' share price might be too optimistic. The Simply Wall St Community’s two fair value estimates for Tango Therapeutics range from US$10.00 to US$12.71 per share. While these span a relatively narrow band, the broader market remains focused on clinical milestones and capital needs. Exploring these alternative viewpoints can be useful as the company’s financial and research balance continues to face real-world challenges. Explore 2 other fair value estimates on Tango Therapeutics - why the stock might be worth as much as 63% more than the current price! Disagree with this assessment? Cr...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin [email protected] [email protected]